ASCO Annual Meeting: Lung Cancer

Thoracic radiotherapy along with prophylactic cranial irradiation (PCI) significantly prolonged progression-free and overall survival in patients with extensive-stage small-cell lung cancer, according to results of a new study presented at ASCO.

The addition of the MET-targeting antibody onartuzumab to erlotinib added no benefit, and may have been detrimental, to patients with MET-amplified stage IIIb/IV metastatic non–small-cell lung cancer, according to a new phase III trial.

As part of our coverage of the 2014 ASCO Annual Meeting, we discuss chemotherapy's curative role in treating lung cancer.

Implementation of a national lung cancer screening program using low-dose CT will identify almost 55,000 additional lung cancer cases over 5 years, but will add $9.3 billion to Medicare expenditures.

A novel agent known as AZD9291 showed promising results in a phase I dose escalation trial among non-small-cell lung cancer (NSCLC) patients whose disease progresses after treatment with EGFR-targeting tyrosine kinase inhibitors.